SEC Form 4 · accession 0001193125-26-374352
Kalaris Therapeutics, Inc. · KLRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amy O'Leary Vandekop
Officer — VP, Corporate Controller
Period of report
Aug 27, 2026
Accepted (ET)
Aug 28, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001754068
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.10 | Aug 27, 2026 | A | 10,000 | A | — | Aug 26, 2036 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The option was granted on August 27, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on August 1, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.